Table 2.

HRs and 95% CI for death following stage III ovarian cancer according to BMI and covariates

VariablesAdjusted HR* (95% CI), n = 294Adjusted HR (95% CI), n = 290
Current age (per y)1.01 (1.00-1.03)1.01 (1.00-1.03)
Histologic type
    Serous adenocarcinomas1.00 (Reference)1.00 (Reference)
    Nonserous carcinomas1.40 (1.02-1.90)1.66 (1.21-2.27)
Primary surgery radical
    Yes0.36 (0.22-0.60)0.36 (0.21-0.60)
    No1.00 (Reference)1.00 (Reference)
    No, only biopsy2.16 (1.54-3.02)2.17 (1.54-3.07)
Platinum-based chemotherapy
    Yes1.00 (Reference)1.00 (Reference)
    No2.80 (1.81-4.34)3.93 (2.49-6.21)
BMI 5 y before diagnosis (kg/m2)
    <18.51.30 (0.66-2.57)1.07 (0.54-2.14)
    18.5-24.91.00 (Reference)1.00 (Reference)
    ≥25.01.71 (1.30-2.25)1.83 (1.38-2.42)
Continuous per BMI unit
    For BMI < 18.50.88 (0.49-1.60)0.91 (0.49-1.69)
    For BMI ≥ 18.51.04 (1.01-1.07)1.05 (1.02-1.08)
BMI at age 20-29 y (kg/m2)
    <18.51.04 (0.69-1.57)1.20 (0.79-1.84)
    18.5-24.91.00 (Reference)1.00 (Reference)
    ≥25.01.72 (1.15-2.58)1.30 (0.81-2.10)
Continuous per BMI unit
    For BMI < 18.50.72 (0.52-1.00)0.81 (0.59-1.12)
    For BMI ≥ 18.51.06 (1.01-1.11)1.01 (0.94-1.08)
  • * Adjusted for current age, radicality of surgery, histology, and platinum-based chemotherapy.

  • Adjusted for current age, radicality of surgery, histology, platinum-based chemotherapy, smoking status, and continuous BMI 5 years before diagnosis.